Combined interferon-α and interleukin-2 as adjuvant treatment for melanoma [6]

Lancet

Volumn 352, Issue 9131, 1998, Pages 908-909

  Dummer, R ^a   Hauschild, A ^a   Henseler, T ^a   Burg, G ^a  

^a UNIVERSITY OF KIEL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT INTERLEUKIN 2;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; FLU LIKE SYNDROME; HUMAN; LETTER; LEUKOPENIA; MAJOR CLINICAL STUDY; MELANOMA; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA; THYROID DISEASE;

EID: 0032511593     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)60052-9     Document Type: Letter

References (5)

1. JM Kirkwood Adjuvant IFNa2 therapy of melanoma Lancet 351 1998 1901 1903
2. JJ Grob B Dreno delaSalmoniere P Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1·5 mm without clinically detectable node metastases Lancet 351 1998 1905 1910
3. ES Schultz R Dummer JC Becker D Zillikens G Burg Influence of various cytokines on the interleukin-2-dependent lysis of melanoma cells in vitro Arch Dermatol Res 286 1994 73 76
4. R Dummer A Hauschild J Kreusch A prospective randomized multicenter trial for the adjuvant treatment of primary highrisk melanoma using s.c. interleukin-2 and interferon-α Melanoma Res 5 1995 445
5. A Davis-Daneshfar R Boni von Wussow P Joller H Burg G Dummer R Adjuvant immunotherapy in malignant melanoma: impact of antibody formation against interferon-alpha on immunoparameters in vivo J Immunother 20 1997 208 213